Breaking News Instant updates and real-time market news.

MYL

Mylan

$31.36

-0.31 (-0.98%)

06:21
11/06/18
11/06
06:21
11/06/18
06:21

Mylan says board hasn't put timeline on strategic alternatives

Mylan said on Monday it had not set any timeline on evaluating its strategic alternatives. "I can assure you the board is busy looking at lots of things... But we put no timeframes around that," CEO Heather Bresch said on the company's Q3 earnings conference call. In August, Mylan's board formed a review committee to evaluate a "wide range" of alternatives.

  • 13

    Nov

MYL Mylan
$31.36

-0.31 (-0.98%)

10/09/18
10/09/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Exelon (EXC) downgraded to Neutral from Overweight at JPMorgan and to Neutral from Buy at Citi. 2. CommScope (COMM) downgraded to Neutral from Buy at Goldman Sachs with analyst Mark Delaney saying he views the company's fundamental environment as "mixed" and views the stock's valuation as fair at current levels. 3. Mylan (MYL) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst David Risinger saying recent generics trends leave him seeing downside risk to consensus forecasts and Mylan's 2018 guidance. 4. Blackbaud (BLKB) downgraded to Market Perform from Outperform at Raymond James and JMP Securities as well as to Hold from Buy at Benchmark. 5. Kroger (KR) downgraded to Sell from Hold at Deutsche Bank while Smart & Final Stores (SFS) was downgraded to Hold from Buy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/12/18
WELS
10/12/18
NO CHANGE
WELS
Market Perform
Merck returning Lantus biosimilar rights negative for Mylan, says Wells Fargo
Wells Fargo analyst David Maris sees a negative read-through for Mylan regarding yesterday's news of Merck Sharp & Dohme Research returning the rights to biosimilar Lantus to Samsung Bioepis. While some view this as a positive, as there will likely be one fewer competitor in the market if Mylan-Biocon make it to the U.S. market, that is a "simplistic and optimistic" take, Maris tells investors in a research note. The more important factor to consider is the "why" Merck dropped out, rather than the number of competitors, the analyst writes. He believes Merck returned the rights to Samsung Bioepis due to the deteriorating pricing environment and pricing outlook for insulin and Lantus biosimilars. Lilly's and Sanofi's manufacturing capacity, along with aggressive discounting, has created a "severe pricing environment," Maris contends. He believes that if Samsung Bioepis and Merck can't make the economics work, than one should be skeptical of Mylan and Biocon having substantial success. Maris has a Market Perform rating on Mylan shares.
10/18/18
WELS
10/18/18
NO CHANGE
WELS
Sandoz results 'potential warning signal' for generics, says Wells Fargo
Wells Fargo analyst David Maris views this morning's results from Novartis' (NVS) generic unit Sandoz as "another negative datapoint" for generic stocks, notably Teva (TEVA), Mylan (MYL) and Amneal Pharmaceuticals (AMNX). Novartis reported Sandoz net sales of $2.4B, down 4% on constant currency, and noted that sales were pressured by 8% pricing erosion in the quarter, Maris tells investors in a research note. Novartis also highlighted that U.S sales for Sandoz declined 17% due to "industry wide pricing pressure," Maris points out. The analyst views the quarter as a "potential warning signal" for the Q3 earnings season for companies with large U.S. commodity generic exposure. He maintains his caution on "generic industry margin risks."
11/01/18
WELS
11/01/18
NO CHANGE
WELS
Market Perform
Fear of missing out helping to push Teva, Mylan higher, says Wells Fargo
Wells Fargo analyst David Maris believes Teva (TEVA) shares are bouncing back to fair value from recent declines after the company reported Q3 earnings that beat his above consensus estimate and hosted a "surprisingly bullish" quarterly call. He also sees a spillover effect occurring with Mylan (MYL) as the generic sector's advance reinforces buyers' belief that the stocks are undervalued and investors' "fear of missing out" drives increased interest. While Maris acknowledges Ajovy, Austedo, cost cuts and tax management are doing well, he believes much of Teva's business continues to show significant challenges and keeps a Market Perform rating on the shares.

TODAY'S FREE FLY STORIES

IRWD

Ironwood

$11.96

0.32 (2.75%)

06:01
11/19/18
11/19
06:01
11/19/18
06:01
Recommendations
Ironwood analyst commentary  »

Ironwood price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

06:00
11/19/18
11/19
06:00
11/19/18
06:00
General news
FX Action: USD-JPY has retained a heavy tone »

FX Action: USD-JPY has…

YETI

Yeti

$16.99

0.1 (0.59%)

05:59
11/19/18
11/19
05:59
11/19/18
05:59
Initiation
Yeti initiated  »

Yeti initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

RHHBY

Roche

$0.00

(0.00%)

05:57
11/19/18
11/19
05:57
11/19/18
05:57
Downgrade
Roche rating change  »

Roche downgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

  • 24

    Dec

NVS

Novartis

$87.74

0.52 (0.60%)

05:56
11/19/18
11/19
05:56
11/19/18
05:56
Upgrade
Novartis rating change  »

Novartis upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 03

    Dec

TI

Telecom Italia

$6.02

0.12 (2.03%)

05:53
11/19/18
11/19
05:53
11/19/18
05:53
Hot Stocks
Telecom Italia appoints Luigi Gubitosi as CEO »

On Sunday, the company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STNE

StoneCo

$25.31

0.69 (2.80%)

05:51
11/19/18
11/19
05:51
11/19/18
05:51
Initiation
StoneCo initiated  »

StoneCo initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

AZN

AstraZeneca

$40.67

-0.685 (-1.66%)

05:51
11/19/18
11/19
05:51
11/19/18
05:51
Downgrade
AstraZeneca rating change  »

AstraZeneca downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 03

    Dec

JPDYY

Japan Display

$0.00

(0.00%)

05:49
11/19/18
11/19
05:49
11/19/18
05:49
Downgrade
Japan Display rating change  »

Japan Display downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTRX

Retrophin

$25.17

0.44 (1.78%)

05:46
11/19/18
11/19
05:46
11/19/18
05:46
Initiation
Retrophin initiated  »

Retrophin initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

YETI

Yeti

$16.99

0.1 (0.59%)

05:43
11/19/18
11/19
05:43
11/19/18
05:43
Initiation
Yeti initiated  »

Yeti initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

EOLS

Evolus

$14.75

0.06 (0.41%)

05:40
11/19/18
11/19
05:40
11/19/18
05:40
Hot Stocks
Evolus announces conditional acceptance from FDA for Jeuveau brand name »

Evolus announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

MNK

Mallinckrodt

$30.85

-0.58 (-1.85%)

05:39
11/19/18
11/19
05:39
11/19/18
05:39
Upgrade
Mallinckrodt rating change  »

Mallinckrodt upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

CPAC

Cementos Pacasmayo

$9.98

(0.00%)

05:38
11/19/18
11/19
05:38
11/19/18
05:38
Upgrade
Cementos Pacasmayo rating change  »

Cementos Pacasmayo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VKTX

Viking Therapeutics

$11.65

0.27 (2.37%)

05:38
11/19/18
11/19
05:38
11/19/18
05:38
Upgrade
Viking Therapeutics rating change  »

Viking Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JD

JD.com

$23.04

-1.18 (-4.87%)

05:37
11/19/18
11/19
05:37
11/19/18
05:37
Earnings
Breaking Earnings news story on JD.com »

JD.com sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

MDGL

Madrigal Pharmaceuticals

$129.47

-3.36 (-2.53%)

05:36
11/19/18
11/19
05:36
11/19/18
05:36
Downgrade
Madrigal Pharmaceuticals rating change  »

Madrigal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

JD

JD.com

$23.04

-1.18 (-4.87%)

05:35
11/19/18
11/19
05:35
11/19/18
05:35
Earnings
JD.com reports Q3 EPS 15c, consensus 10c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

AMH

American Homes 4 Rent

$19.83

-0.04 (-0.20%)

05:35
11/19/18
11/19
05:35
11/19/18
05:35
Downgrade
American Homes 4 Rent rating change  »

American Homes 4 Rent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BB

BlackBerry

$8.97

0.12 (1.36%)

05:35
11/19/18
11/19
05:35
11/19/18
05:35
Upgrade
BlackBerry rating change  »

BlackBerry upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMAX

RE/MAX Holdings

$30.26

-0.23 (-0.75%)

05:34
11/19/18
11/19
05:34
11/19/18
05:34
Upgrade
RE/MAX Holdings rating change  »

RE/MAX Holdings upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

RNG

RingCentral

$76.41

-0.54 (-0.70%)

05:34
11/19/18
11/19
05:34
11/19/18
05:34
Upgrade
RingCentral rating change  »

RingCentral upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMTD

TD Ameritrade

05:33
11/19/18
11/19
05:33
11/19/18
05:33
Upgrade
TD Ameritrade rating change  »

TD Ameritrade upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHW

Charles Schwab

$46.97

-0.35 (-0.74%)

05:33
11/19/18
11/19
05:33
11/19/18
05:33
Downgrade
Charles Schwab rating change  »

Charles Schwab downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSANY

Nissan

$0.00

(0.00%)

05:32
11/19/18
11/19
05:32
11/19/18
05:32
Hot Stocks
Nissan finds 'significant acts of misconduct' by Representative Director »

Nissan said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.